What pharmacokinetic studies support interaction between ivermectin and cyp3a inhibitors?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Clinical pharmacology studies show that ivermectin is primarily metabolized by CYP3A4 and that strong CYP3A/P‑gp inhibitors can raise ivermectin exposure in animal models and microsomes; a mini‑pig ketoconazole challenge increased ivermectin exposure (proof‑of‑concept) and ketoconazole increased ivermectin plasma levels in dogs, while human reviews find ivermectin to be at most a weak CYP inhibitor and note limited clinical interaction data [1] [2] [3] [4] [5].
1. What the basic pharmacokinetics say: CYP3A4 is the main metabolizer
In vitro human liver microsome work identified CYP3A4 as the predominant enzyme producing multiple ivermectin metabolites; specific inhibition of CYP3A4 reduced metabolite formation by ~90%, establishing CYP3A4 as the main metabolic pathway for ivermectin [1].
2. Animal pharmacokinetic interaction studies: ketoconazole raises ivermectin levels
Two controlled animal pharmacokinetic experiments show clear interaction: a mini‑pig study used ketoconazole, a broad CYP3A4 (and P‑gp) inhibitor, as a proof‑of‑concept and reported enhanced ivermectin pharmacokinetics in the host [2]. A separate dog study demonstrated that multiple oral doses of ketoconazole “dramatically altered” ivermectin pharmacokinetics, increasing systemic exposure and residence time — changes the authors linked to P‑gp and CYP3A effects and warned about neurotoxicity risk if P‑gp at the blood‑brain barrier is inhibited [3].
3. In vitro inhibition data: ivermectin is weak as an inhibitor of CYPs
Laboratory enzyme studies and reviews indicate ivermectin can inhibit several P450 enzymes but only at relatively high concentrations: reported IC50 values ranged broadly and suggest ivermectin is “no or weak inhibitor” of CYP3A4 and other P450s in those assays. That supports the idea ivermectin is principally a substrate of CYP3A4 rather than a clinically important perpetrator of CYP3A inhibition [4] [6].
4. Translational gap: animal and microsomal findings vs. human clinical evidence
Available human clinical interaction data are scarce. The Liverpool COVID‑19 interactions database treats ivermectin as a CYP3A4 and P‑gp substrate and states ivermectin “does not inhibit or induce CYPs or P‑gp,” adding that co‑administration with many drugs “has not been studied” and a clinically significant interaction is considered unlikely on pharmacokinetic grounds [5]. That position contrasts with animal proof‑of‑concept data showing meaningful exposure increases when strong inhibitors are used [2] [3].
5. Where the evidence points: risk with strong CYP3A/P‑gp inhibitors, uncertainty with weak/moderate inhibitors
Regulatory practice for CYP3A substrates generally uses strong inhibitors (ketoconazole, itraconazole) in worst‑case DDI studies; the animal data using ketoconazole conform to that approach and signal potential for increased ivermectin exposure when strong CYP3A/P‑gp inhibitors are present [2] [3] [7]. However, human clinical DDI trials with strong inhibitors or broad population pharmacokinetic studies documenting magnitude of effect in people are not reported in the provided sources — available sources do not mention human clinical trials that quantify how much CYP3A inhibitors change ivermectin exposure in humans [5] [1].
6. Safety implications and mechanistic concerns: P‑gp at the blood‑brain barrier matters
Authors emphasize dual mechanisms: CYP3A4 inhibition can reduce systemic clearance while P‑gp inhibition can increase brain penetration. The dog study explicitly linked ketoconazole’s effect on both CYP3A and P‑gp to higher systemic concentrations and cautioned about neurotoxicity if P‑gp at the blood‑brain barrier is inhibited [3]. The mini‑pig study also highlighted the overlapping effects of CYP3A and P‑gp inhibition and proposed that differential IC50s might allow safe CYP inhibition without measurable CSF increases — but that conclusion arises from a specific animal model and not clinical human data [2].
7. Competing perspectives and key limitations
Perspective A (mechanistic/animal): strong CYP3A/P‑gp inhibitors can meaningfully increase ivermectin exposure [2] [3]. Perspective B (clinical guidance/reviews): ivermectin is mainly a substrate, not an appreciable inhibitor/inducer in humans, and clinically significant DDIs are considered unlikely absent direct human data [5] [4]. Major limitation: human interaction trials quantifying effects of strong, moderate, and weak CYP3A inhibitors on ivermectin pharmacokinetics are not described in the sources provided (available sources do not mention such human trials) [5] [1].
8. Practical takeaways for clinicians and researchers
Mechanistic and animal studies justify caution: co‑administration of ivermectin with strong CYP3A4 and/or P‑gp inhibitors (e.g., ketoconazole used experimentally) can raise exposure and potentially CNS risk; however, definitive human pharmacokinetic interaction magnitudes remain unreported in the sources provided, so clinicians must balance mechanistic plausibility with the absence of clinical DDI quantification and monitor for adverse effects when combining such drugs [2] [3] [5].
If you want, I can compile the animal study data (dose, fold‑increase in AUC/Cmax) and the microsomal inhibition metrics from the cited papers to produce a focused table for prescribers and investigators.